Igyxos S.A. has completed a Series A fundraising
Igyxos S.A. has completed a US$8.4 million fundraising as part of a Series A funding led by Bpifrance through its FABS Fund, with participation from the Go Capital Amorçage II and Loire Valley Invest Funds and by the Emergence Innovation II. This will allow the founder Marie Christine Maurel and Professor René Frydman, joined by Pierre-Henry Longeray (ex Merck Serono) as CEO, to pursue the proof of concept in human clinical practice.
Based in Nouzilly, France, biotechnology startup Igyxos is developing a new treatment for female and male infertility that works by shifting hormonal imbalances with a new method using monoclonal antibodies.
Oaklins’ team in France advised Igyxos on a "dual-track" project that allowed them to validate with the industry both scientific and therapeutic interest of its drug candidate based on the use of monoclonal antibodies to improve the treatment of female and male infertility.
CSO and Founder, Igyxos, S.A.
Talk to the deal team
Senior AdvisorParis, France
Associate DirectorParis, France
Westminster Homecare has been acquired by Care at Home
The private shareholders of Westminster Homecare Ltd. have sold the company to Care at Home Services (South East) Ltd.Learn more
RVC Medical IT has been acquired by NEXUS AG
Main Capital Partners B.V. has sold RVC Medical IT B.V. to NEXUS AG.Learn more
SCS Computers has been acquired by MAPS Group
The private shareholders of SCS Computers, an Italian software company specialized in the healthcare sector, have sold the company to MAPS Group.Learn more